ClinicalTrials.gg
Active, not recruitingNCT03052608Updated Nov 25, 2025Results posted

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

A Phase 3 interventional study of Lorlatinib and Crizotinib in Carcinoma, Non-Small-Cell Lung, sponsored by Pfizer. Active, not recruiting at 166 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-25.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
296
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung — 8 open to participants now, 16 under way, 1 of them phase 3. lorlatinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
2nd of 27
296 · median 45
Started
2017
with 2 others
Phase 3
Only one
of the 27
Primary completion
2020-03
later than 0 of 15 live
Registered
4th of 27
by date
Lead sponsor
8 of 27
Pfizer

Among the 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung, this one is the 2nd largest by enrollment, is one of 3 that started in 2017, is the only one in phase 3, reaches primary completion later than 0 of the 15 other live ones, and was the 4th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About lorlatinib

lorlatinib: first FDA approval 2018 (LORBRENA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC patients who are treatment naïve and to compare lorlatinib to crizotinib with respect to overall survival in the same population

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung

Keywords

  • ALK; anaplastic lymphoma kinase; Non-Small-Cell Lung cancer; NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of locally advanced or ALK-positive NSCLC; at least 1 extracranial measurable target lesion not previously irradiated. allowed if asymptomatic and not currently requiring treatment.
  • Availability of an archival FFPE tissue specimen.
  • No prior systemic NSCLC treatment.
  • PS 0, 1, or 2.
  • Age ≥18 years .
  • Adequate Bone Marrow, Liver, Renal, Pancreatic Function
  • Negative pregnancy test for females of

Exclusion criteria

Exclusion Criteria:

  • Spinal cord compression unless good pain control attained
  • Major surgery within 4 weeks prior to randomization.
  • Radiation therapy within 2 weeks prior to randomization, including stereotactic or partial brain irradiation. Whole brain irradiation within 4 weeks prior to randomization
  • Active bacterial, fungal, or viral infection
  • cardiovascular disease, active or within 3 months prior to enrollment. Ongoing cardiac dysrhythmias, uncontrolled atrial fibrillation, bradycardia or congenital long syndrome
  • Predisposing characteristics for acute pancreatitis in the last month prior to randomization.
  • History of extensive, disseminated, bilateral or presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease
  • Active (other than NSCLC, non melanoma skin cancer, in situ cervical cancer, papillary thyroid cancer, LCIS/DCIS of the breast, or localized prostate cancer) within the last 3 years prior to randomization.
  • Concurrent use of any of the following food or drugs within 12 days prior to the first dose of lorlatinib or crizotinib.

    1. known strong inhibitors .
    2. known strong CYP3A inducers
    3. known P gp substrates with a narrow therapeutic index
  • Concurrent use of CYP3A substrates with narrow therapeutic indices within 12 days prior to the first dose of lorlatinib or crizotinib.
  • Other severe acute or chronic medical or psychiatric condition, including recent or active suicidal ideation or behavior, or laboratory abnormality that may increase the risk associated with study participation or interfere with the interpretation of study results
  • site staff members directly involved in the conduct of the study and their family members, or Pfizer employees, including their family members, directly involved in the conduct of the study.
  • Participation in other studies involving investigational drug(s) within 2 weeks prior to study entry and/or during study participation.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
296 participants (actual)

Study arms

  • Experimental
    Lorlatinib

    Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously

    Drug: Lorlatinib

  • Active comparator
    Crizotinib

    Crizotinib single agent, 250 mg (1 x 250) oral capsules, BID, continuously

    Drug: Crizotinib

Interventions

  • ALK-positive NSCL treatment

    Also known as: PF-06463922

  • ALK-positive NSCL treatment

    Also known as: Xalkori

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) Assessment

    PFS was defined as the time from randomization to the date of the first documentation of progressive disease as assessed by the independent radiologist or death due to any cause, whichever occurred first. PFS (in months) was calculated as (date of event or censoring-randomization+1)/30.4375. Progressive disease is defined per RECIST version 1.1, as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of 1 or more new lesions.

    Time frame: From time of Study Start up to 33 months

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from randomization to the date of death due to any cause. OS (in months) was calculated as (date of death or censoring - start date +1)/30.4375. Participants last known to be alive were censored at date of last contact.

    Time frame: From time of Study Start up to 33 months

  2. Progression-Free Survival (PFS) Based on Investigator's Assessment

    PFS was defined as the time from randomization to the date of the first documentation of progressive disease as assessed by investigator or death due to any cause, whichever occurred first. PFS (in months) was calculated as (date of event or censoring-randomization+1)/30.4375. Progressive disease is defined per RECIST version 1.1, as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of 1 or more new lesions.

    Time frame: From time of Study Start up to 33 months

  3. Objective Response Rate (ORR) - Percentage of Participants With Objective Response (OR) Based on BICR Assessment

    ORR was the percentage of participants with objective response of complete response (CR) or partial response (PR) according to RECIST version 1.1 recorded from randomization until disease progression or start of new anti-cancer therapy. CR was defined as complete disappearance of all target lesions and non-target disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). PR was defined as at least a 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

    Time frame: From time of Study Start up to 33 months

  4. Objective Response Rate (ORR) - Percentage of Participants With Objective Response (OR) Based on Investigator's Assessment

    ORR was the percentage of participants with objective response of complete response (CR) or partial response (PR) according to RECIST version 1.1 recorded from randomization until disease progression or start of new anti-cancer therapy. CR was defined as complete disappearance of all target lesions and non-target disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). PR was defined as at least a 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

    Time frame: From time of Study Start up to 33 months

  5. Intracranial Objective Response Rate (IC-ORR) - Percentage of Participants With Intracranial Objective Response (IC-OR) Based on BICR Assessment

    IC-ORR was the percentage of participant with intracranial objective response of complete response (CR) or partial response (PR) based on intracranial disease in the subset of participants with at least 1 intracranial lesion per RECIST version 1.1 (modified) recorded from randomization until disease progression or start of new anti-cancer therapy. CR was defined as complete disappearance of all target lesions and non-target disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). PR was defined as at least a 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

    Time frame: From time of Study Start up to 33 months

  6. Intracranial Time to Progression (IC-TTP) Based on BICR Assessment

    IC-TTP based on BICR assessment was defined as the time from date of randomization to the date of the first documentation of progression of intracranial disease, based on either new brain metastases or progression of existing brain metastases.

    Time frame: From time of Study Start up to 33 months

  7. Duration of Response (DR) Based on BICR Assessment

    DR was defined, for participants with a confirmed objective response (OR) of complete response (CR) or partial response (PR) per RECIST version 1.1, as the time from the first documentation of OR to the first documentation of progressive disease (PD) or death due to any cause, whichever occurred first. CR was defined as complete disappearance of all target lesions and non-target disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). PR was defined as at least a 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of 1 or more new lesions.

    Time frame: From time of Study Start up to 33 months

  8. Intracranial Duration of Response (IC-DR) Based on BICR Assessment

    IC-DR was defined, for participants with a confirmed intracranial objective response (OR) of complete response (CR) or partial response (PR) per RECIST version 1.1, as the time from the first documentation of intracranial OR to the first documentation of intracranial progressive disease (PD) or death due to any cause, whichever occurred first. CR was defined as complete disappearance of all target lesions and non-target disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). PR was defined as at least a 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of 1 or more new lesions.

    Time frame: From time of Study Start up to 33 months

  9. Time to Tumor Response (TTR) Based on BICR Assessment

    TTR based on BICR assessment was defined, for participants with a confirmed objective response, as the time from the date of randomization to the first documentation of objective response (complete response or partial response) which was subsequently confirmed. Complete response was defined as complete disappearance of all target lesions and non-target disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). Partial response was defined as at least a 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

    Time frame: From time of Study Start up to 33 months

  10. Intracranial Time to Tumor Response (IC-TTR) Based on BICR Assessment

    IC-TTR was defined, for participants with a confirmed intracranial objective response, as the time from the date of randomization to the first documentation of intracranial objective response (complete response or partial response) which was subsequently confirmed. Complete response was defined as complete disappearance of all target lesions and non-target disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). Partial response was defined as at least a 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

    Time frame: From time of Study Start up to 33 months

  11. PFS2 Based on Investigator's Assessment

    PFS2 was defined as the time from randomization to the date of progression of disease on first subsequent systemic anti-cancer therapy, or death from any cause, whichever occurred first

    Time frame: From time of Study Start up to 45 months

  12. Number of Participants With Treatment-Emergent Adverse Events (AEs; All-Causality and Treatment-Related)

    An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes: death, life-threatening experience, initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. All AEs in the table below were treatment-emergent AEs. Grade 3 and 4 AEs in the table below indicated severe AE and life-threatening consequences respectively; Grade 5 indicated death due to AE. Treatment-related AEs were determined by investigators.

    Time frame: From time of Study Start up to 33 months

  13. Number of Participants With Changes in Hematology Laboratory Parameters From Baseline Maximum NCI-CTCAE Grade Lower Than 3 to Postbaseline Maximum Grade 3 or Grade 4

    Laboratory test results were graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grades 1 and 2 indicate mild and moderate AE, respectively; Grades 3 and 4 indicate severe AE and life-threatening consequences respectively; Grade 5 indicates death due to AE. Participants with laboratory test abnormalities were summarized according to the worst grade for each laboratory test result. All participants meeting the postbaseline grade criteria in the table below had baseline maximum grades lower than 3.

    Time frame: From Baseline up to 33 months

  14. Number of Participants With Changes in Chemistry Laboratory Parameters From Baseline Maximum NCI-CTCAE Grade Lower Than 3 to Postbaseline Maximum Grade 3 or Grade 4

    Laboratory test results were graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grades 1 and 2 indicate mild and moderate AE, respectively; Grades 3 and 4 indicate severe AE and life-threatening consequences respectively; Grade 5 indicates death due to AE. Participants with laboratory test abnormalities were summarized according to the worst grade for each laboratory test result. All participants meeting the postbaseline grade criteria in the table below had baseline maximum grades lower than 3.

    Time frame: From Baseline up to 33 months

  15. Number of Participants With Changes in Lipid Laboratory Parameters From Baseline Maximum NCI-CTCAE Grade Lower Than 3 to Postbaseline Maximum Grade 3 or Grade 4

    Laboratory test results were graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grades 1 and 2 indicate mild and moderate AE, respectively; Grades 3 and 4 indicate severe AE and life-threatening consequences respectively; Grade 5 indicates death due to AE. Participants with laboratory test abnormalities were summarized according to the worst grade for each laboratory test result. All participants meeting the postbaseline grade criteria in the table below had baseline maximum grades lower than 3.

    Time frame: From Baseline up to 33 months

  16. Number of Participant With Vital Signs and Body Weight Data Meeting Pre-defined Criteria

    Vital signs data included pulse, systolic blood pressure, and diastolic blood pressure. Measurements were only provided once per timepoint. If multiple assessments were provided per timepoint, the maximum value were used for reporting. The pre-defined criteria of vital sign and body weight data were as follows: maximum pulse rate \>120 beats per minute (bpm); minimum pulse rate \<50 bpm; maximum increase in pulse rate ≥30 bpm; maximum decrease in pulse rate ≥30 bpm; increase in systolic blood Pressure ≥40 mmHg; decrease in systolic blood pressure ≥40 mmHg; decrease in systolic blood pressure ≥60 mmHg; increase in diastolic blood pressure ≥20 mmHg; decrease in diastolic blood pressure ≥20 mmHg; decrease in diastolic blood pressure ≥40 mmHg; increase in body weight ≥10%; increase in body weight ≥20%; decrease in body weight ≥10%.

    Time frame: From Baseline up to 33 months

  17. Number of Participant With Maximum Increase From Baseline in Electrocardiogram (ECG) Data Meeting Pre-defined Criteria

    Baseline was defined as the last assessment performed on or prior to date of the first dose of study treatment. Triplicate ECGs were collected in the study and the average of the replicate assessments were used for summary analysis. The pre-defined criteria of ECG data were as follows: change from baseline in QTcF ≥60 msec, ≥30 msec but \<60 msec, \<30 msec; change from baseline in QTcB ≥60 msec, ≥30 msec but \<60 msec, \<30 msec; PR change ≥50% if absolute baseline value was \<200 msec; PR change ≥25% if absolute baseline value was ≥200 msec; QRS change ≥50% if absolute baseline value was \<100 msec; QRS change ≥25% if absolute baseline value was ≥100 msec.

    Time frame: From Baseline up to 33 months

  18. Number of Participants With Maximum Decrease From Baseline Greater Than or Equal to 20 Points in Left Ventricular Ejection Fraction (LVEF) Percentage

    In this outcome measure, baseline was defined as the last assessment on or prior to the date of the first dose of study treatment. Decrease from baseline was an absolute difference between baseline and observed value.

    Time frame: From Baseline up to 33 months

  19. Change From Baseline in Total Scores of Beck Depression Inventory (BDI)-II (Mood Assessment) Across Time

    BDI-II (Mood Assessment) is a 21 item self-reported scale, with each item rated by participants on a 4-point scale (ranging from 0-3). The scale includes items capturing mood, (loss of pleasure, sadness, and irritability), suicidal ideation, and cognitive signs (punitive thoughts, self-criticism, self-dislike pessimism, poor concentration) as well as somatic signs (appetite, sleep, fatigue, libido). Scores were obtained by adding up the total points from the series of answers. The total score ranged from 0 to 63, with higher total scores indicating more severe depressive symptoms. The standardized cutoffs are as follows: 0-13: minimal depression; 14-19: mild depression; 20-28: moderate depression; 29-63: severe depression.

    Time frame: Baseline, Cycle 2 Day 1 (C2D1), C3D1, C4D1, C5D1, C6D1, C8D1, C10D1, C12D1, C14D1, C16D1, C18D1, C20D1, C22D1, C24D1, C26D1, C28D1, C30D1, C32D1, C34D1, C36D1, C38D1 and End of Treatment

  20. Number of Participants With Suicidal Ideation and Suicidal Behavior Across Time

    Suicidal ideation and behaviors were assessed by the Columbia Suicide Severity Rating Scale (C-SSRS). The C-SSRS is a unique, simple and short method of assessing both behavior and ideation that tracks all suicidal events and provides a summary of suicidality. It assesses the lethality of attempts and other features of ideation (frequency, duration, controllability, reasons for ideation, and deterrents), all of which are significantly predictive of completed suicide.

    Time frame: Baseline, Cycle 2 Day 1 (C2D1), C3D1, C4D1, C5D1, C6D1, C8D1, C10D1, C12D1, C14D1, C16D1, C18D1, C20D1, C22D1, C24D1, C26D1, C28D1, C30D1, C32D1, C34D1, C36D1, C38D1 and End of Treatment

  21. Change From Baseline in Global Quality of Life (QOL), Functional Scales and Symptoms Scales as Assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) During Overall Treatment

    The EORTC QLQ C30 consists of 30 questions and includes 5 functional scales (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale; 3 symptom scales (fatigue, pain, nausea and vomiting); and 6 single items that assess additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and financial impact. All scales and single item measures range in score from 0 to 100. Higher scores on the functional scales represent higher levels of functioning. Higher scores on the global health status/quality of life scale represent higher health status/quality of life. Higher scores on symptom scales/items represent a greater presence of symptoms.

    Time frame: From Baseline up to Cycle 38 Day 1

  22. Change From Baseline in Lung Cancer Symptoms as Assessed by the EORTC Quality of Life Questionnaire-Lung Cancer 13 (QLQ- LC13) During Overall Treatment

    The EORTC QLQ LC13 consists of 13 questions and includes 1 multi-item scale and 9 single items assessing symptoms (dyspnea, cough, haemoptysis, and site-specific pain), side effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication use. The scale scores rang from 0 to 100, with higher scores indicating higher ("worse") level of symptoms.

    Time frame: From Baseline up to Cycle 38 Day 1

  23. Change From Baseline in Health Status as Assessed by EuroQol 5 Dimension 5 Level (EQ-5D-5L) - Visual Analogue Scale (VAS) Across Time

    The EuroQol EQ-5D-5L is a participant-completed questionnaire designed to assess health status. There are 2 components to the EuroQol EQ-5D-5L: a descriptive system in which individuals rate their level of problems (none, slight, moderate, severe, extreme/unable) in 5 areas (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a VAS. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) and higher scores indicate better health state.

    Time frame: Baseline, Day 1 of all cycles from Cycle 2 to Cycle 38, and End of Treatment

  24. Change From Baseline in Health Status as Assessed by EuroQol 5 Dimension 5 Level (EQ-5D-5L) - Index Across Time

    The EuroQol EQ-5D-5L is a participant-completed questionnaire designed to assess health status. There are 2 components to the EuroQol EQ-5D-5L: a descriptive system in which individuals rate their level of problems (none, slight, moderate, severe, extreme/unable) in 5 areas (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a VAS in which participants rate their overall health status from 0 (worst imaginable) to 100 (best imaginable). EQ-5D summary index is obtained with a formula that weights each level of the 5 dimensions. The index-based score is interpreted along a continuum of 0 (death) to 1 (perfect health).

    Time frame: Baseline, Day 1 of all cycles from Cycle 2 to Cycle 38, and End of Treatment

  25. Time to Deterioration (TTD) in Participant Reported Pain in Chest, Dyspnea, or Cough From QLQ-LC13

    The EORTC QLQ LC13 consists of 13 questions and includes 1 multi-item scale and 9 single items assessing symptoms (dyspnea, cough, haemoptysis, and site-specific pain), side effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication use. The scale scores rang from 0 to 100, with higher scores indicating higher ("worse") level of symptoms. TTD in pain in chest, dyspnea, or cough was defined as the time from randomization to the first time the participant's score showed a 10 point or greater increase after baseline in any of the 3 symptoms. TTD in months was calculated as (date of deterioration or censoring - randomization date +1)/30.4375.

    Time frame: From Baseline up to 33 months

  26. Number of Participant With ALK Domain Mutation in Plasma Circulating Nucleic Acid (CNA) Analysis at Screening, Cycle 2 Day 1 and Cycle 7 Day 1

    The analysis of anaplastic lymphoma kinase (ALK) domain mutation in plasma CNA was performed by next-generation sequencing (NGS) and the number of participants with one or more ALK mutations at Screening, Cycle 2 Day 1 and Cycle 7 Day 1 is presented here.

    Time frame: at Screening, Cycle 2 Day 1 and Cycle 7 Day 1

  27. Number of Participant With ALK Fusion Variant in Plasma Circulating Nucleic Acid (CNA) Analysis at Screening, Cycle 2 Day 1 and Cycle 7 Day 1

    The analysis of ALK fusion variant in plasma CNA was performed by NGS and the number of participants with fusion variants at Screening, Cycle 2 Day 1 and Cycle 7 Day 1 is presented here. In the table below, EML4-ALK is the abbreviation of echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase.

    Time frame: at Screening, Cycle 2 Day 1 and Cycle 7 Day 1

07

Results

Posted Apr 1, 2021

Participant flow

This phase 3, randomized, open label study was conducted at 104 sites in 23 countries. A total of 296 participants were randomized, 149 to the lorlatinib arm and 147 to the crizotinib arm.

Treatment Phase
Participant flow — Treatment Phase
MilestoneLorlatinibCrizotinib
Started149147
Completed2683
Not completed12364
Withdrew: Adverse event1012
Withdrew: Death64
Withdrew: Withdrawal by subject412
Withdrew: Global deterioration of health status03
Withdrew: Subject decided to continue study treatment as per clinical practice in another hospital.01
Withdrew: Subject didn't receive study treatment.01
Withdrew: Ongoing10331
Long-Term Follow-up Phase
Participant flow — Long-Term Follow-up Phase
MilestoneLorlatinibCrizotinib
Started149147
Completed00
Not completed149147
Withdrew: Death2328
Withdrew: Lost to follow-up02
Withdrew: Withdrawal by subject418
Withdrew: Ongoing12299

Outcome measures

PrimaryProgression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) Assessment

PFS was defined as the time from randomization to the date of the first documentation of progressive disease as assessed by the independent radiologist or death due to any cause, whichever occurred first. PFS (in months) was calculated as (date of event or censoring-randomization+1)/30.4375. Progressive disease is defined per RECIST version 1.1, as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of 1 or more new lesions.

Time frame:
From time of Study Start up to 33 months
Reported as:
Median · Months
Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) Assessment
MonthsLorlatinibCrizotinib
Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) AssessmentNA (NA to NA)9.3 (7.6 to 11.1)
Statistical analysis
  • Lorlatinib vs Crizotinib · one-sided stratified log-rank · p = <0.0001 (The study was to be considered positive if the 1-sided log-rank test for PFS, stratified for baseline stratification factors (ethnicity and brain metastases) was significant at the 0.0081 level at the cutoff date of this report.) · Hazard ratio (hr): 0.28 · 95% CI 0.191 to 0.413Based on Cox Proportional Hazards model stratified by the presence of brain metastases and ethnic origin at randomization. Assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of Lorlatinib.
SecondaryOverall Survival (OS)

OS was defined as the time from randomization to the date of death due to any cause. OS (in months) was calculated as (date of death or censoring - start date +1)/30.4375. Participants last known to be alive were censored at date of last contact.

Time frame:
From time of Study Start up to 33 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsLorlatinibCrizotinib
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Lorlatinib vs Crizotinib · Hazard ratio (hr): 0.72 · 95% CI 0.414 to 1.249Based on Cox Proportional Hazards model stratified by the presence of brain metastases and ethnic origin at randomization. Assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of Lorlatinib.
SecondaryProgression-Free Survival (PFS) Based on Investigator's Assessment

PFS was defined as the time from randomization to the date of the first documentation of progressive disease as assessed by investigator or death due to any cause, whichever occurred first. PFS (in months) was calculated as (date of event or censoring-randomization+1)/30.4375. Progressive disease is defined per RECIST version 1.1, as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of 1 or more new lesions.

Time frame:
From time of Study Start up to 33 months
Reported as:
Median · Months
Progression-Free Survival (PFS) Based on Investigator's Assessment
MonthsLorlatinibCrizotinib
Progression-Free Survival (PFS) Based on Investigator's AssessmentNA (NA to NA)9.1 (7.4 to 10.9)
Statistical analysis
  • Lorlatinib vs Crizotinib · one-sided stratified log-rank · p = <0.0001 · Hazard ratio (hr): 0.21 · 95% CI 0.144 to 0.307Based on Cox Proportional Hazards model stratified by the presence of brain metastases and ethnic origin at randomization. Assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of Lorlatinib.
SecondaryObjective Response Rate (ORR) - Percentage of Participants With Objective Response (OR) Based on BICR Assessment

ORR was the percentage of participants with objective response of complete response (CR) or partial response (PR) according to RECIST version 1.1 recorded from randomization until disease progression or start of new anti-cancer therapy. CR was defined as complete disappearance of all target lesions and non-target disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). PR was defined as at least a 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

Time frame:
From time of Study Start up to 33 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) - Percentage of Participants With Objective Response (OR) Based on BICR Assessment
Percentage of participantsLorlatinibCrizotinib
Objective Response Rate (ORR) - Percentage of Participants With Objective Response (OR) Based on BICR Assessment75.8 (68.2 to 82.5)57.8 (49.4 to 65.9)
Statistical analysis
  • Lorlatinib vs Crizotinib · Cochran-Mantel-Haenszel · p = 0.0005 · Odds ratio (or): 2.254 · 95% CI 1.353 to 3.891Odds ratio was estimated using Mantel-Haenszel method. An odds ratio larger than 1 indicates better outcome for Lorlatinib relative to Crizotinib. Exact CI was calculated.
SecondaryObjective Response Rate (ORR) - Percentage of Participants With Objective Response (OR) Based on Investigator's Assessment

ORR was the percentage of participants with objective response of complete response (CR) or partial response (PR) according to RECIST version 1.1 recorded from randomization until disease progression or start of new anti-cancer therapy. CR was defined as complete disappearance of all target lesions and non-target disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). PR was defined as at least a 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

Time frame:
From time of Study Start up to 33 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) - Percentage of Participants With Objective Response (OR) Based on Investigator's Assessment
Percentage of participantsLorlatinibCrizotinib
Objective Response Rate (ORR) - Percentage of Participants With Objective Response (OR) Based on Investigator's Assessment80.5 (73.3 to 86.6)61.9 (53.5 to 69.8)
Statistical analysis
  • Lorlatinib vs Crizotinib · Cochran-Mantel-Haenszel · p = 0.0002 · Odds ratio (or): 2.499 · 95% CI 1.484 to 4.594Odds ratio was estimated using Mantel-Haenszel method. An odds ratio larger than 1 indicates better outcome for Lorlatinib relative to Crizotinib. Exact CI was calculated.
SecondaryIntracranial Objective Response Rate (IC-ORR) - Percentage of Participants With Intracranial Objective Response (IC-OR) Based on BICR Assessment

IC-ORR was the percentage of participant with intracranial objective response of complete response (CR) or partial response (PR) based on intracranial disease in the subset of participants with at least 1 intracranial lesion per RECIST version 1.1 (modified) recorded from randomization until disease progression or start of new anti-cancer therapy. CR was defined as complete disappearance of all target lesions and non-target disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). PR was defined as at least a 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

Time frame:
From time of Study Start up to 33 months
Reported as:
Number · Percentage of participants
Intracranial Objective Response Rate (IC-ORR) - Percentage of Participants With Intracranial Objective Response (IC-OR) Based on BICR Assessment
Percentage of participantsLorlatinibCrizotinib
Intracranial Objective Response Rate (IC-ORR) - Percentage of Participants With Intracranial Objective Response (IC-OR) Based on BICR Assessment65.8 (48.6 to 80.4)20.0 (9.1 to 35.6)
Statistical analysis
  • Lorlatinib vs Crizotinib · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 8.407 · 95% CI 2.586 to 27.233Odds ratio was estimated using Mantel-Haenszel method. An odds ratio larger than 1 indicates better outcome for Lorlatinib relative to Crizotinib. Exact CI was calculated.
SecondaryIntracranial Time to Progression (IC-TTP) Based on BICR Assessment

IC-TTP based on BICR assessment was defined as the time from date of randomization to the date of the first documentation of progression of intracranial disease, based on either new brain metastases or progression of existing brain metastases.

Time frame:
From time of Study Start up to 33 months
Reported as:
Median · Months
Intracranial Time to Progression (IC-TTP) Based on BICR Assessment
MonthsLorlatinibCrizotinib
Intracranial Time to Progression (IC-TTP) Based on BICR AssessmentNA (NA to NA)16.6 (11.1 to NA)
Statistical analysis
  • Lorlatinib vs Crizotinib · one-sided stratified log-rank · p = <0.0001 · Hazard ratio (hr): 0.07 · 95% CI 0.026 to 0.170Based on Cox Proportional Hazards model stratified by the presence of brain metastases and ethnic origin at randomization. Assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of Lorlatinib.
SecondaryDuration of Response (DR) Based on BICR Assessment

DR was defined, for participants with a confirmed objective response (OR) of complete response (CR) or partial response (PR) per RECIST version 1.1, as the time from the first documentation of OR to the first documentation of progressive disease (PD) or death due to any cause, whichever occurred first. CR was defined as complete disappearance of all target lesions and non-target disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). PR was defined as at least a 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of 1 or more new lesions.

Time frame:
From time of Study Start up to 33 months
Reported as:
Median · Months
Duration of Response (DR) Based on BICR Assessment
MonthsLorlatinibCrizotinib
Duration of Response (DR) Based on BICR AssessmentNA (NA to NA)11.0 (9.0 to 12.9)
SecondaryIntracranial Duration of Response (IC-DR) Based on BICR Assessment

IC-DR was defined, for participants with a confirmed intracranial objective response (OR) of complete response (CR) or partial response (PR) per RECIST version 1.1, as the time from the first documentation of intracranial OR to the first documentation of intracranial progressive disease (PD) or death due to any cause, whichever occurred first. CR was defined as complete disappearance of all target lesions and non-target disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). PR was defined as at least a 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of 1 or more new lesions.

Time frame:
From time of Study Start up to 33 months
Reported as:
Median · Months
Intracranial Duration of Response (IC-DR) Based on BICR Assessment
MonthsLorlatinibCrizotinib
Intracranial Duration of Response (IC-DR) Based on BICR AssessmentNA (NA to NA)9.4 (6.0 to 11.1)
SecondaryTime to Tumor Response (TTR) Based on BICR Assessment

TTR based on BICR assessment was defined, for participants with a confirmed objective response, as the time from the date of randomization to the first documentation of objective response (complete response or partial response) which was subsequently confirmed. Complete response was defined as complete disappearance of all target lesions and non-target disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). Partial response was defined as at least a 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

Time frame:
From time of Study Start up to 33 months
Reported as:
Median · Months
Time to Tumor Response (TTR) Based on BICR Assessment
MonthsLorlatinibCrizotinib
Time to Tumor Response (TTR) Based on BICR Assessment1.8 (1.7 to 1.9)1.8 (1.7 to 1.9)
SecondaryIntracranial Time to Tumor Response (IC-TTR) Based on BICR Assessment

IC-TTR was defined, for participants with a confirmed intracranial objective response, as the time from the date of randomization to the first documentation of intracranial objective response (complete response or partial response) which was subsequently confirmed. Complete response was defined as complete disappearance of all target lesions and non-target disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). Partial response was defined as at least a 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

Time frame:
From time of Study Start up to 33 months
Reported as:
Median · Months
Intracranial Time to Tumor Response (IC-TTR) Based on BICR Assessment
MonthsLorlatinibCrizotinib
Intracranial Time to Tumor Response (IC-TTR) Based on BICR Assessment1.9 (1.8 to 3.7)1.8 (1.7 to 2.7)
SecondaryPFS2 Based on Investigator's Assessment

PFS2 was defined as the time from randomization to the date of progression of disease on first subsequent systemic anti-cancer therapy, or death from any cause, whichever occurred first

Time frame:
From time of Study Start up to 45 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AEs; All-Causality and Treatment-Related)

An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes: death, life-threatening experience, initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. All AEs in the table below were treatment-emergent AEs. Grade 3 and 4 AEs in the table below indicated severe AE and life-threatening consequences respectively; Grade 5 indicated death due to AE. Treatment-related AEs were determined by investigators.

Time frame:
From time of Study Start up to 33 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs; All-Causality and Treatment-Related)
ParticipantsLorlatinibCrizotinib
AEs (all-causality)149140
AEs (treatment-related)144133
SAEs (all-causality)5139
SAEs (treatment-related)127
Maximum Grade 3 or 4 AEs (all-causality)10879
Maximum Grade 3 or 4 AEs (treatment-related)8352
Maximum Grade 5 AEs (all-causality)77
Maximum Grade 5 AEs (treatment-related)20
AEs causing study discontinuation (all-causality)78
AEs causing study discontinuation (treatment-related)20
AEs causing study treatment discontinuation (all-causality)1013
AEs causing study treatment discontinuation (treatment-related)77
AEs causing dose reduction or temporary discontinuation (all-causality)7971
AEs causing dose reduction or temporary discontinuation (treatment-related)6054
SecondaryNumber of Participants With Changes in Hematology Laboratory Parameters From Baseline Maximum NCI-CTCAE Grade Lower Than 3 to Postbaseline Maximum Grade 3 or Grade 4

Laboratory test results were graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grades 1 and 2 indicate mild and moderate AE, respectively; Grades 3 and 4 indicate severe AE and life-threatening consequences respectively; Grade 5 indicates death due to AE. Participants with laboratory test abnormalities were summarized according to the worst grade for each laboratory test result. All participants meeting the postbaseline grade criteria in the table below had baseline maximum grades lower than 3.

Time frame:
From Baseline up to 33 months
Reported as:
Count of participants · Participants
Number of Participants With Changes in Hematology Laboratory Parameters From Baseline Maximum NCI-CTCAE Grade Lower Than 3 to Postbaseline Maximum Grade 3 or Grade 4
ParticipantsLorlatinibCrizotinib
Anemia (Postbaseline Maximum Grade 3)34
Anemia (Postbaseline Maximum Grade 4)NANA
Hemoglobin increased (Postbaseline Maximum Grade 3)00
Hemoglobin increased (Postbaseline Maximum Grade 4)NANA
Lymphocyte count decreased (Postbaseline Maximum Grade 3)27
Lymphocyte count decreased (Postbaseline Maximum Grade 4)21
Lymphocyte count increased (Postbaseline Maximum Grade 3)00
Lymphocyte count increased (Postbaseline Maximum Grade 4)NANA
Neutrophil count decreased (Postbaseline Maximum Grade 3)119
Neutrophil count decreased (Postbaseline Maximum Grade 4)14
Platelet count decreased (Postbaseline Maximum Grade 3)01
Platelet count decreased (Postbaseline Maximum Grade 4)00
White blood cell decreased (Postbaseline Maximum Grade 3)05
White blood cell decreased (Postbaseline Maximum Grade 4)00
SecondaryNumber of Participants With Changes in Chemistry Laboratory Parameters From Baseline Maximum NCI-CTCAE Grade Lower Than 3 to Postbaseline Maximum Grade 3 or Grade 4

Laboratory test results were graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grades 1 and 2 indicate mild and moderate AE, respectively; Grades 3 and 4 indicate severe AE and life-threatening consequences respectively; Grade 5 indicates death due to AE. Participants with laboratory test abnormalities were summarized according to the worst grade for each laboratory test result. All participants meeting the postbaseline grade criteria in the table below had baseline maximum grades lower than 3.

Time frame:
From Baseline up to 33 months
Reported as:
Count of participants · Participants
Number of Participants With Changes in Chemistry Laboratory Parameters From Baseline Maximum NCI-CTCAE Grade Lower Than 3 to Postbaseline Maximum Grade 3 or Grade 4
ParticipantsLorlatinibCrizotinib
Alanine aminotransferase increased (Postbaseline Maximum Grade 3)45
Alanine aminotransferase increased (Postbaseline Maximum Grade 4)01
Alkaline phosphate increased (Postbaseline Maximum Grade 3)01
Alkaline phosphate increased (Postbaseline Maximum Grade 4)00
Aspartate aminotransferase increased (Postbaseline Maximum Grade 3)34
Aspartate aminotransferase increased (Postbaseline Maximum Grade 4)01
Blood bilirubin increased (Postbaseline Maximum Grade 3)00
Blood bilirubin increased (Postbaseline Maximum Grade 4)00
Creatine kinase increased (Postbaseline Maximum Grade 3)35
Creatine kinase increased (Postbaseline Maximum Grade 4)02
Creatinine increased (Postbaseline Maximum Grade 3)13
Creatinine increased (Postbaseline Maximum Grade 4)00
Gamma glutamyl transferase increased (Postbaseline Maximum Grade 3)98
Gamma glutamyl transferase increased (Postbaseline Maximum Grade 4)01
Hypercalcemia (Postbaseline Maximum Grade 3)00
Hypercalcemia (Postbaseline Maximum Grade 4)00
Hyperglycemia (Postbaseline Maximum Grade 3)93
Hyperglycemia (Postbaseline Maximum Grade 4)10
Hyperkalemia (Postbaseline Maximum Grade 3)23
Hyperkalemia (Postbaseline Maximum Grade 4)00
Hypermagnesemia (Postbaseline Maximum Grade 3)21
Hypermagnesemia (Postbaseline Maximum Grade 4)00
Hypernatremia (Postbaseline Maximum Grade 3)00
Hypernatremia (Postbaseline Maximum Grade 4)00
Hypoalbuminemia (Postbaseline Maximum Grade 3)19
Hypoalbuminemia (Postbaseline Maximum Grade 4)NANA
Hypocalcemia (Postbaseline Maximum Grade 3)10
Hypocalcemia (Postbaseline Maximum Grade 4)00
Hypoglycemia (Postbaseline Maximum Grade 3)00
Hypoglycemia (Postbaseline Maximum Grade 4)01
Hypokalemia (Postbaseline Maximum Grade 3)03
Hypokalemia (Postbaseline Maximum Grade 4)00
Hypomagnesemia (Postbaseline Maximum Grade 3)00
Hypomagnesemia (Postbaseline Maximum Grade 4)00
Hyponatremia (Postbaseline Maximum Grade 3)510
Hyponatremia (Postbaseline Maximum Grade 4)01
Hypophosphatemia (Postbaseline Maximum Grade 3)34
Hypophosphatemia (Postbaseline Maximum Grade 4)00
Lipase increased (Postbaseline Maximum Grade 3)86
Lipase increased (Postbaseline Maximum Grade 4)31
Serum amylase increased (Postbaseline Maximum Grade 3)12
Serum amylase increased (Postbaseline Maximum Grade 4)00
SecondaryNumber of Participants With Changes in Lipid Laboratory Parameters From Baseline Maximum NCI-CTCAE Grade Lower Than 3 to Postbaseline Maximum Grade 3 or Grade 4

Laboratory test results were graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grades 1 and 2 indicate mild and moderate AE, respectively; Grades 3 and 4 indicate severe AE and life-threatening consequences respectively; Grade 5 indicates death due to AE. Participants with laboratory test abnormalities were summarized according to the worst grade for each laboratory test result. All participants meeting the postbaseline grade criteria in the table below had baseline maximum grades lower than 3.

Time frame:
From Baseline up to 33 months
Reported as:
Count of participants · Participants
Number of Participants With Changes in Lipid Laboratory Parameters From Baseline Maximum NCI-CTCAE Grade Lower Than 3 to Postbaseline Maximum Grade 3 or Grade 4
ParticipantsLorlatinibCrizotinib
Cholesterol high (Postbaseline Maximum Grade 3)260
Cholesterol high (Postbaseline Maximum Grade 4)30
Hypertriglyceridemia (Postbaseline Maximum Grade 3)200
Hypertriglyceridemia (Postbaseline Maximum Grade 4)130
SecondaryNumber of Participant With Vital Signs and Body Weight Data Meeting Pre-defined Criteria

Vital signs data included pulse, systolic blood pressure, and diastolic blood pressure. Measurements were only provided once per timepoint. If multiple assessments were provided per timepoint, the maximum value were used for reporting. The pre-defined criteria of vital sign and body weight data were as follows: maximum pulse rate \>120 beats per minute (bpm); minimum pulse rate \<50 bpm; maximum increase in pulse rate ≥30 bpm; maximum decrease in pulse rate ≥30 bpm; increase in systolic blood Pressure ≥40 mmHg; decrease in systolic blood pressure ≥40 mmHg; decrease in systolic blood pressure ≥60 mmHg; increase in diastolic blood pressure ≥20 mmHg; decrease in diastolic blood pressure ≥20 mmHg; decrease in diastolic blood pressure ≥40 mmHg; increase in body weight ≥10%; increase in body weight ≥20%; decrease in body weight ≥10%.

Time frame:
From Baseline up to 33 months
Reported as:
Count of participants · Participants
Number of Participant With Vital Signs and Body Weight Data Meeting Pre-defined Criteria
ParticipantsLorlatinibCrizotinib
Sitting pulse rate: pulse >120 bpm71
Sitting pulse rate: pulse <50 bpm422
Sitting pulse rate: change ≥30 bpm increase243
Sitting pulse rate: change ≥30 bpm decrease1747
Sitting systolic blood pressure: change ≥40 mmHg increase223
Sitting systolic blood pressure: change ≥40 mmHg decrease614
Sitting systolic blood pressure: change ≥60 mmHg decrease01
Sitting diastolic blood pressure: change ≥20 mmHg increase4118
Sitting diastolic blood pressure: change ≥20 mmHg decrease2652
Sitting diastolic blood pressure: change ≥40 mmHg decrease01
Body weight (kg): percent change from baseline ≥10% increase9939
Body weight (kg): percent change from baseline ≥20% increase353
Body weight (kg): percent change from baseline ≥10% decrease612
SecondaryNumber of Participant With Maximum Increase From Baseline in Electrocardiogram (ECG) Data Meeting Pre-defined Criteria

Baseline was defined as the last assessment performed on or prior to date of the first dose of study treatment. Triplicate ECGs were collected in the study and the average of the replicate assessments were used for summary analysis. The pre-defined criteria of ECG data were as follows: change from baseline in QTcF ≥60 msec, ≥30 msec but \<60 msec, \<30 msec; change from baseline in QTcB ≥60 msec, ≥30 msec but \<60 msec, \<30 msec; PR change ≥50% if absolute baseline value was \<200 msec; PR change ≥25% if absolute baseline value was ≥200 msec; QRS change ≥50% if absolute baseline value was \<100 msec; QRS change ≥25% if absolute baseline value was ≥100 msec.

Time frame:
From Baseline up to 33 months
Reported as:
Count of participants · Participants
Number of Participant With Maximum Increase From Baseline in Electrocardiogram (ECG) Data Meeting Pre-defined Criteria
ParticipantsLorlatinibCrizotinib
Change of QTcF ≥60 msec516
30 msec ≤ Change of QTcF <60 msec4941
Change of QTcF <30 msec9281
Change of QTcB ≥60 msec1015
30 msec ≤ Change of QTcB <60 msec4926
Change of QTcB <30 msec90100
PR change ≥50% if absolute baseline value was <200 msec84
PR change ≥25% if absolute baseline value was ≥200 msec00
QRS change ≥50% if absolute baseline value was <100 msec23
QRS change ≥25% if absolute baseline value was ≥100 msec20
SecondaryNumber of Participants With Maximum Decrease From Baseline Greater Than or Equal to 20 Points in Left Ventricular Ejection Fraction (LVEF) Percentage

In this outcome measure, baseline was defined as the last assessment on or prior to the date of the first dose of study treatment. Decrease from baseline was an absolute difference between baseline and observed value.

Time frame:
From Baseline up to 33 months
Reported as:
Count of participants · Participants
Number of Participants With Maximum Decrease From Baseline Greater Than or Equal to 20 Points in Left Ventricular Ejection Fraction (LVEF) Percentage
ParticipantsLorlatinibCrizotinib
Number of Participants With Maximum Decrease From Baseline Greater Than or Equal to 20 Points in Left Ventricular Ejection Fraction (LVEF) Percentage21
SecondaryChange From Baseline in Total Scores of Beck Depression Inventory (BDI)-II (Mood Assessment) Across Time

BDI-II (Mood Assessment) is a 21 item self-reported scale, with each item rated by participants on a 4-point scale (ranging from 0-3). The scale includes items capturing mood, (loss of pleasure, sadness, and irritability), suicidal ideation, and cognitive signs (punitive thoughts, self-criticism, self-dislike pessimism, poor concentration) as well as somatic signs (appetite, sleep, fatigue, libido). Scores were obtained by adding up the total points from the series of answers. The total score ranged from 0 to 63, with higher total scores indicating more severe depressive symptoms. The standardized cutoffs are as follows: 0-13: minimal depression; 14-19: mild depression; 20-28: moderate depression; 29-63: severe depression.

Time frame:
Baseline, Cycle 2 Day 1 (C2D1), C3D1, C4D1, C5D1, C6D1, C8D1, C10D1, C12D1, C14D1, C16D1, C18D1, C20D1, C22D1, C24D1, C26D1, C28D1, C30D1, C32D1, C34D1, C36D1, C38D1 and End of Treatment
Reported as:
Mean · Units on a scale
Change From Baseline in Total Scores of Beck Depression Inventory (BDI)-II (Mood Assessment) Across Time
Units on a scaleLorlatinibCrizotinib
Cycle 2 Day 1-1.8 ± 5.52-1.2 ± 5.62
Cycle 3 Day 1-2.5 ± 5.85-2.7 ± 5.78
Cycle 4 Day 1-2.9 ± 5.73-3.6 ± 6.60
Cycle 5 Day 1-2.5 ± 6.28-3.0 ± 6.24
Cycle 6 Day 1-2.6 ± 6.61-2.9 ± 6.65
Cycle 8 Day 1-3.2 ± 6.18-1.9 ± 6.56
Cycle 10 Day 1-3.0 ± 6.30-2.6 ± 5.98
Cycle 12 Day 1-3.6 ± 6.05-2.1 ± 6.23
Cycle 14 Day 1-3.3 ± 6.82-2.5 ± 5.57
Cycle 16 Day 1-3.3 ± 6.87-2.3 ± 5.77
Cycle 18 Day 1-3.7 ± 7.26-2.6 ± 4.30
Cycle 20 Day 1-3.3 ± 6.24-2.4 ± 4.62
Cycle 22 Day 1-3.2 ± 6.95-2.5 ± 4.82
Cycle 24 Day 1-3.1 ± 5.972.3 ± 9.31
Cycle 26 Day 1-3.2 ± 6.87-0.8 ± 3.81
Cycle 28 Day 1-3.0 ± 6.530.2 ± 7.65
Cycle 30 Day 1-4.8 ± 8.001.3 ± 3.20
Cycle 32 Day 1-5.0 ± 14.147.5 ± 9.19
Cycle 34 Day 1-2.3 ± 12.420.0
Cycle 36 Day 1—0.0
End of Treatment0.8 ± 4.49-0.2 ± 7.45
SecondaryNumber of Participants With Suicidal Ideation and Suicidal Behavior Across Time

Suicidal ideation and behaviors were assessed by the Columbia Suicide Severity Rating Scale (C-SSRS). The C-SSRS is a unique, simple and short method of assessing both behavior and ideation that tracks all suicidal events and provides a summary of suicidality. It assesses the lethality of attempts and other features of ideation (frequency, duration, controllability, reasons for ideation, and deterrents), all of which are significantly predictive of completed suicide.

Time frame:
Baseline, Cycle 2 Day 1 (C2D1), C3D1, C4D1, C5D1, C6D1, C8D1, C10D1, C12D1, C14D1, C16D1, C18D1, C20D1, C22D1, C24D1, C26D1, C28D1, C30D1, C32D1, C34D1, C36D1, C38D1 and End of Treatment
Reported as:
Count of participants · Participants
Number of Participants With Suicidal Ideation and Suicidal Behavior Across Time
ParticipantsLorlatinibCrizotinib
Baseline37
Cycle 2 Day 105
Cycle 3 Day 111
Cycle 4 Day 101
Cycle 5 Day 101
Cycle 6 Day 102
Cycle 8 Day 102
Cycle 10 Day 101
Cycle 12 Day 100
Cycle 14 Day 100
Cycle 16 Day 100
Cycle 18 Day 100
Cycle 20 Day 100
Cycle 22 Day 100
Cycle 24 Day 101
Cycle 26 Day 110
Cycle 28 Day 100
Cycle 30 Day 100
Cycle 32 Day 100
Cycle 34 Day 100
Cycle 36 Day 100
Cycle 38 Day 10—
End of Treatment00
SecondaryChange From Baseline in Global Quality of Life (QOL), Functional Scales and Symptoms Scales as Assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) During Overall Treatment

The EORTC QLQ C30 consists of 30 questions and includes 5 functional scales (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale; 3 symptom scales (fatigue, pain, nausea and vomiting); and 6 single items that assess additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and financial impact. All scales and single item measures range in score from 0 to 100. Higher scores on the functional scales represent higher levels of functioning. Higher scores on the global health status/quality of life scale represent higher health status/quality of life. Higher scores on symptom scales/items represent a greater presence of symptoms.

Time frame:
From Baseline up to Cycle 38 Day 1
Reported as:
Mean · Units on a scale
Change From Baseline in Global Quality of Life (QOL), Functional Scales and Symptoms Scales as Assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) During Overall Treatment
Units on a scaleLorlatinibCrizotinib
Global QOL8.60 (6.09 to 11.11)3.95 (1.15 to 6.76)
Physical Functioning4.84 (2.67 to 7.01)2.82 (0.42 to 5.22)
Role Functioning6.86 (4.05 to 9.68)4.78 (1.61 to 7.95)
Emotional Functioning8.77 (6.88 to 10.67)6.20 (4.09 to 8.30)
Cognitive Functioning-4.20 (-6.56 to -1.84)-1.02 (-3.64 to 1.60)
Social Functioning7.00 (4.48 to 9.52)4.72 (1.87 to 7.57)
Fatigue-9.93 (-12.61 to -7.26)-4.26 (-7.28 to -1.25)
Nausea and Vomiting-4.35 (-5.79 to -2.90)3.51 (1.89 to 5.14)
Pain-4.60 (-7.17 to -2.02)-5.76 (-8.67 to -2.85)
Dyspnoea-7.02 (-9.66 to -4.39)-8.75 (-11.76 to -5.74)
Insomnia-17.34 (-19.71 to -14.96)-9.39 (-12.07 to -6.71)
Appetite Loss-13.15 (-15.00 to -11.30)-3.95 (-6.01 to -1.88)
Constipation-2.40 (-5.33 to 0.54)2.53 (-0.83 to 5.90)
Diarrhea-0.92 (-3.42 to 1.59)11.12 (8.33 to 13.91)
Financial Difficulties-6.79 (-9.52 to -4.05)-5.74 (-8.80 to -2.68)
Statistical analysis
  • Lorlatinib vs Crizotinib · Mixed Models Analysis · p = 0.0096 · Mean difference (net): 4.65 · 95% CI 1.14 to 8.16
  • Lorlatinib vs Crizotinib · Mixed Models Analysis · p = 0.1897 · Mean difference (net): 2.02 · 95% CI -1.01 to 5.05
  • Lorlatinib vs Crizotinib · Mixed Models Analysis · p = 0.2999 · Mean difference (net): 2.09 · 95% CI -1.87 to 6.04
  • Lorlatinib vs Crizotinib · Mixed Models Analysis · p = 0.0553 · Mean difference (net): 2.58 · 95% CI -0.06 to 5.22
  • Lorlatinib vs Crizotinib · Mixed Models Analysis · p = 0.0588 · Mean difference (net): -3.18 · 95% CI -6.47 to 0.12
  • Lorlatinib vs Crizotinib · Mixed Models Analysis · p = 0.2118 · Mean difference (net): 2.27 · 95% CI -1.30 to 5.85
  • Lorlatinib vs Crizotinib · Mixed Models Analysis · p = 0.0032 · Mean difference (net): -5.67 · 95% CI -9.42 to -1.92
  • Lorlatinib vs Crizotinib · Mixed Models Analysis · p = <0.0001 · Mean difference (net): -7.86 · 95% CI -9.86 to -5.86
  • Lorlatinib vs Crizotinib · Mixed Models Analysis · p = 0.5310 · Mean difference (net): 1.16 · 95% CI -2.49 to 4.82
  • Lorlatinib vs Crizotinib · Mixed Models Analysis · p = 0.3602 · Mean difference (net): 1.72 · 95% CI -1.98 to 5.43
  • Lorlatinib vs Crizotinib · Mixed Models Analysis · p = <0.0001 · Mean difference (net): -7.95 · 95% CI -11.25 to -4.64
  • Lorlatinib vs Crizotinib · Mixed Models Analysis · p = <0.0001 · Mean difference (net): -9.21 · 95% CI -11.80 to -6.62
  • Lorlatinib vs Crizotinib · Mixed Models Analysis · p = 0.0198 · Mean difference (net): -4.93 · 95% CI -9.07 to -0.79
  • Lorlatinib vs Crizotinib · Mixed Models Analysis · p = <0.0001 · Mean difference (net): -12.03 · 95% CI -15.49 to -8.58
  • Lorlatinib vs Crizotinib · Mixed Models Analysis · p = 0.5947 · Mean difference (net): -1.04 · 95% CI -4.90 to 2.82
SecondaryChange From Baseline in Lung Cancer Symptoms as Assessed by the EORTC Quality of Life Questionnaire-Lung Cancer 13 (QLQ- LC13) During Overall Treatment

The EORTC QLQ LC13 consists of 13 questions and includes 1 multi-item scale and 9 single items assessing symptoms (dyspnea, cough, haemoptysis, and site-specific pain), side effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication use. The scale scores rang from 0 to 100, with higher scores indicating higher ("worse") level of symptoms.

Time frame:
From Baseline up to Cycle 38 Day 1
Reported as:
Mean · Units on a scale
Change From Baseline in Lung Cancer Symptoms as Assessed by the EORTC Quality of Life Questionnaire-Lung Cancer 13 (QLQ- LC13) During Overall Treatment
Units on a scaleLorlatinibCrizotinib
Dyspnoea-4.36 (-6.55 to -2.17)-4.90 (-7.34 to -2.47)
Coughing-21.21 (-23.71 to -18.70)-16.66 (-19.48 to -13.84)
Haemoptysis-2.53 (-3.12 to -1.94)-2.65 (-3.34 to -1.97)
Sore Mouth0.56 (-0.98 to 2.10)-0.60 (-2.39 to 1.19)
Dysphagia-1.35 (-2.95 to 0.25)0.16 (-1.68 to 2.00)
Peripheral Neuropathy11.56 (8.21 to 14.91)6.20 (2.39 to 10.00)
Alopecia1.61 (-0.97 to 4.20)1.81 (-1.08 to 4.70)
Pain in Chest-9.54 (-11.27 to -7.80)-9.01 (-10.97 to -7.05)
Pain in Arm or Shoulder-6.93 (-9.43 to -4.43)-7.38 (-10.24 to -4.52)
Pain in Other Parts-2.31 (-5.28 to 0.66)-5.67 (-8.97 to -2.38)
Statistical analysis
  • Lorlatinib vs Crizotinib · Mixed Models Analysis · p = 0.7254 · Mean difference (net): 0.55 · 95% CI -2.51 to 3.60
  • Lorlatinib vs Crizotinib · Mixed Models Analysis · p = 0.0115 · Mean difference (net): -4.55 · 95% CI -8.06 to -1.03
  • Lorlatinib vs Crizotinib · Mixed Models Analysis · p = 0.7824 · Mean difference (net): 0.12 · 95% CI -0.75 to 0.99
  • Lorlatinib vs Crizotinib · Mixed Models Analysis · p = 0.2988 · Mean difference (net): 1.16 · 95% CI -1.04 to 3.36
  • Lorlatinib vs Crizotinib · Mixed Models Analysis · p = 0.1916 · Mean difference (net): -1.51 · 95% CI -3.79 to 0.76
  • Lorlatinib vs Crizotinib · Mixed Models Analysis · p = 0.0279 · Mean difference (net): 5.37 · 95% CI 0.59 to 10.15
  • Lorlatinib vs Crizotinib · Mixed Models Analysis · p = 0.9162 · Mean difference (net): -0.20 · 95% CI -3.89 to 3.49
  • Lorlatinib vs Crizotinib · Mixed Models Analysis · p = 0.6698 · Mean difference (net): -0.53 · 95% CI -2.96 to 1.90
  • Lorlatinib vs Crizotinib · Mixed Models Analysis · p = 0.8035 · Mean difference (net): 0.45 · 95% CI -3.13 to 4.04
  • Lorlatinib vs Crizotinib · Mixed Models Analysis · p = 0.1143 · Mean difference (net): 3.36 · 95% CI -0.82 to 7.55
SecondaryChange From Baseline in Health Status as Assessed by EuroQol 5 Dimension 5 Level (EQ-5D-5L) - Visual Analogue Scale (VAS) Across Time

The EuroQol EQ-5D-5L is a participant-completed questionnaire designed to assess health status. There are 2 components to the EuroQol EQ-5D-5L: a descriptive system in which individuals rate their level of problems (none, slight, moderate, severe, extreme/unable) in 5 areas (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a VAS. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) and higher scores indicate better health state.

Time frame:
Baseline, Day 1 of all cycles from Cycle 2 to Cycle 38, and End of Treatment
Reported as:
Mean · Units on a scale
Change From Baseline in Health Status as Assessed by EuroQol 5 Dimension 5 Level (EQ-5D-5L) - Visual Analogue Scale (VAS) Across Time
Units on a scaleLorlatinibCrizotinib
Cycle 2 Day 16.0 (3.33 to 8.72)3.1 (0.19 to 5.92)
Cycle 3 Day 16.0 (3.30 to 8.75)5.3 (2.37 to 8.18)
Cycle 4 Day 17.1 (3.71 to 10.41)5.6 (2.77 to 8.47)
Cycle 5 Day 14.3 (0.39 to 8.13)5.1 (1.88 to 8.26)
Cycle 6 Day 16.5 (3.11 to 9.85)4.5 (1.08 to 7.91)
Cycle 7 Day 15.5 (1.95 to 9.13)4.0 (0.35 to 7.55)
Cycle 8 Day 16.7 (2.95 to 10.37)4.2 (0.63 to 7.68)
Cycle 9 Day 16.4 (2.47 to 10.33)3.9 (0.09 to 7.69)
Cycle 10 Day 17.2 (3.22 to 11.20)3.9 (-0.02 to 7.75)
Cycle 11 Day 18.1 (4.27 to 11.83)2.0 (-1.62 to 5.59)
Cycle 12 Day 17.6 (3.82 to 11.41)4.8 (0.95 to 8.59)
Cycle 13 Day 17.5 (3.91 to 11.11)5.8 (1.99 to 9.51)
Cycle 14 Day 16.7 (3.06 to 10.32)2.3 (-1.33 to 5.91)
Cycle 15 Day 16.1 (2.33 to 9.96)1.5 (-3.14 to 6.07)
Cycle 16 Day 16.9 (2.71 to 11.04)2.4 (-2.89 to 7.71)
Cycle 17 Day 18.3 (4.08 to 12.46)1.1 (-5.05 to 7.17)
Cycle 18 Day 18.7 (4.17 to 13.28)1.3 (-5.01 to 7.56)
Cycle 19 Day 16.8 (1.86 to 11.70)2.8 (-2.79 to 8.44)
Cycle 20 Day 17.9 (2.83 to 13.06)3.4 (-3.59 to 10.44)
Cycle 21 Day 17.2 (1.96 to 12.44)3.3 (-4.06 to 10.64)
Cycle 22 Day 14.5 (-0.51 to 9.48)1.9 (-6.69 to 10.54)
Cycle 23 Day 15.2 (-0.68 to 11.14)-0.6 (-10.97 to 9.81)
Cycle 24 Day 14.9 (-1.22 to 11.09)-3.0 (-21.43 to 15.43)
Cycle 25 Day 14.0 (-2.13 to 10.18)1.4 (-11.86 to 14.75)
Cycle 26 Day 17.9 (1.00 to 14.77)2.0 (-11.84 to 15.84)
Cycle 27 Day 14.6 (-2.37 to 11.57)3.0 (-12.79 to 18.79)
Cycle 28 Day 16.0 (-3.75 to 15.66)2.7 (-13.20 to 18.54)
Cycle 29Day 17.4 (-3.78 to 18.48)8.2 (-11.18 to 27.58)
Cycle 30 Day 19.1 (-5.66 to 23.95)2.8 (-22.92 to 28.42)
Cycle 31 Day 17.8 (-11.84 to 27.51)0.0 (-190.59 to 190.59)
Cycle 32 Day 17.9 (-11.65 to 27.45)2.5 (-156.33 to 161.33)
Cycle 33 Day 14.4 (-21.74 to 30.49)-2.5 (-224.86 to 219.86)
Cycle 34 Day 1-0.5 (-32.20 to 31.20)20.0
Cycle 35 Day 10.0 (-32.48 to 32.48)20.0
Cycle 36 Day 1-4.5 (-315.80 to 306.80)15.0
Cycle 37 Day 1-17.5 (-176.33 to 141.33)—
Cycle 38 Day 125.0—
End of Treatment-3.7 (-13.66 to 6.33)-1.3 (-5.43 to 2.80)
SecondaryChange From Baseline in Health Status as Assessed by EuroQol 5 Dimension 5 Level (EQ-5D-5L) - Index Across Time

The EuroQol EQ-5D-5L is a participant-completed questionnaire designed to assess health status. There are 2 components to the EuroQol EQ-5D-5L: a descriptive system in which individuals rate their level of problems (none, slight, moderate, severe, extreme/unable) in 5 areas (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a VAS in which participants rate their overall health status from 0 (worst imaginable) to 100 (best imaginable). EQ-5D summary index is obtained with a formula that weights each level of the 5 dimensions. The index-based score is interpreted along a continuum of 0 (death) to 1 (perfect health).

Time frame:
Baseline, Day 1 of all cycles from Cycle 2 to Cycle 38, and End of Treatment
Reported as:
Mean · Units on a scale
Change From Baseline in Health Status as Assessed by EuroQol 5 Dimension 5 Level (EQ-5D-5L) - Index Across Time
Units on a scaleLorlatinibCrizotinib
Cycle 2 Day 10.078 (0.0475 to 0.1092)0.064 (0.0258 to 0.1021)
Cycle 3 Day 10.071 (0.0327 to 0.1097)0.101 (0.0665 to 0.1353)
Cycle 4 Day 10.089 (0.0520 to 0.1254)0.098 (0.0619 to 0.1338)
Cycle 5 Day 10.047 (0.0061 to 0.0887)0.100 (0.0626 to 0.1373)
Cycle 6 Day 10.077 (0.0407 to 0.1124)0.070 (0.0324 to 0.1077)
Cycle 7 Day 10.062 (0.0180 to 0.1052)0.046 (0.0002 to 0.0910)
Cycle 8 Day 10.074 (0.0340 to 0.1133)0.061 (0.0201 to 0.1011)
Cycle 9 Day 10.060 (0.0175 to 0.1028)0.050 (0.0082 to 0.0919)
Cycle 10 Day 10.074 (0.0303 to 0.1179)0.050 (0.0168 to 0.0826)
Cycle 11 Day 10.083 (0.0418 to 0.1237)0.057 (0.0222 to 0.0914)
Cycle 12 Day 10.080 (0.0390 to 0.1201)0.049 (0.0118 to 0.0864)
Cycle 13 Day 10.081 (0.0365 to 0.1259)0.055 (0.0165 to 0.0931)
Cycle 14 Day 10.091 (0.0490 to 0.1322)0.021 (-0.0157 to 0.0576)
Cycle 15 Day 10.077 (0.0314 to 0.1217)0.036 (-0.0100 to 0.0811)
Cycle 16 Day 10.091 (0.0469 to 0.1347)0.051 (0.0070 to 0.0953)
Cycle 17 Day 10.098 (0.0523 to 0.1434)-0.016 (-0.1000 to 0.0685)
Cycle 18 Day 10.103 (0.0520 to 0.1531)0.021 (-0.0296 to 0.0716)
Cycle 19 Day 10.100 (0.0481 to 0.1518)0.027 (-0.0246 to 0.0793)
Cycle 20 Day 10.103 (0.0459 to 0.1596)0.025 (-0.0593 to 0.1090)
Cycle 21 Day 10.068 (0.0091 to 0.1276)0.040 (-0.0187 to 0.0989)
Cycle 22 Day 10.079 (0.0134 to 0.1447)0.052 (-0.0249 to 0.1289)
Cycle 23 Day 10.060 (-0.0127 to 0.1324)0.006 (-0.2020 to 0.2133)
Cycle 24 Day 10.082 (0.0104 to 0.1531)-0.053 (-0.2793 to 0.1731)
Cycle 25 Day 10.047 (-0.0287 to 0.1231)0.045 (-0.0289 to 0.1194)
Cycle 26 Day 10.065 (-0.0218 to 0.1519)0.039 (-0.0200 to 0.0978)
Cycle 27 Day 10.042 (-0.0603 to 0.1434)0.021 (-0.0867 to 0.1292)
Cycle 28 Day 10.024 (-0.0911 to 0.1399)-0.040 (-0.1640 to 0.0836)
Cycle 29 Day 10.046 (-0.0836 to 0.1755)0.041 (-0.0108 to 0.0928)
Cycle 30 Day 10.099 (-0.0355 to 0.2306)-0.028 (-0.1740 to 0.1190)
Cycle 31 Day 10.086 (-0.0957 to 0.2683)-0.024 (-0.8558 to 0.8088)
Cycle 32 Day 10.058 (-0.1601 to 0.2767)-0.139 (-2.4320 to 2.1550)
Cycle 33 Day 10.058 (-0.2006 to 0.3163)-0.024 (-0.8558 to 0.8088)
Cycle 34 Day 10.062 (-0.2820 to 0.4057)0.042
Cycle 35 Day 10.129 (-0.1098 to 0.3668)0.042
Cycle 36 Day 1-0.027 (-1.7736 to 1.7206)0.042
Cycle 37 Day 10.056 (-0.6497 to 0.7607)—
Cycle 38 Day 10.232—
End of Treatment-0.033 (-0.1513 to 0.0852)0.001 (-0.0769 to 0.0782)
SecondaryTime to Deterioration (TTD) in Participant Reported Pain in Chest, Dyspnea, or Cough From QLQ-LC13

The EORTC QLQ LC13 consists of 13 questions and includes 1 multi-item scale and 9 single items assessing symptoms (dyspnea, cough, haemoptysis, and site-specific pain), side effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication use. The scale scores rang from 0 to 100, with higher scores indicating higher ("worse") level of symptoms. TTD in pain in chest, dyspnea, or cough was defined as the time from randomization to the first time the participant's score showed a 10 point or greater increase after baseline in any of the 3 symptoms. TTD in months was calculated as (date of deterioration or censoring - randomization date +1)/30.4375.

Time frame:
From Baseline up to 33 months
Reported as:
Median · Months
Time to Deterioration (TTD) in Participant Reported Pain in Chest, Dyspnea, or Cough From QLQ-LC13
MonthsLorlatinibCrizotinib
Time to Deterioration (TTD) in Participant Reported Pain in Chest, Dyspnea, or Cough From QLQ-LC133.3 (2.1 to 4.7)3.7 (2.0 to 5.5)
Statistical analysis
  • Lorlatinib vs Crizotinib · one-sided stratified log-rank · p = 0.7293 · Hazard ratio (hr): 1.09 · 95% CI 0.822 to 1.444Based on Cox Proportional Hazards model stratified by the presence of brain metastases and ethnic origin at randomization. Assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of Lorlatinib.
SecondaryNumber of Participant With ALK Domain Mutation in Plasma Circulating Nucleic Acid (CNA) Analysis at Screening, Cycle 2 Day 1 and Cycle 7 Day 1

The analysis of anaplastic lymphoma kinase (ALK) domain mutation in plasma CNA was performed by next-generation sequencing (NGS) and the number of participants with one or more ALK mutations at Screening, Cycle 2 Day 1 and Cycle 7 Day 1 is presented here.

Time frame:
at Screening, Cycle 2 Day 1 and Cycle 7 Day 1
Reported as:
Count of participants · Participants
Number of Participant With ALK Domain Mutation in Plasma Circulating Nucleic Acid (CNA) Analysis at Screening, Cycle 2 Day 1 and Cycle 7 Day 1
ParticipantsLorlatinibCrizotinib
at Screening — ≥1 ALK Mutation Detected56
at Screening — No ALK Mutation Detected8891
at Screening — No Circulating Free Deoxyribonucleic Acid (cfDNA) Detected3225
at Screening — Other (Sample failed analysis, uninformative, or not analyzed.)53
Cycle 2 Day 1 — ≥1 ALK Mutation Detected23
Cycle 2 Day 1 — No ALK Mutation Detected6655
Cycle 2 Day 1 — No Circulating Free Deoxyribonucleic Acid (cfDNA) Detected5358
Cycle 2 Day 1 — Other (Sample failed analysis, uninformative, or not analyzed.)42
Cycle 7 Day 1 — ≥1 ALK Mutation Detected35
Cycle 7 Day 1 — No ALK Mutation Detected4542
Cycle 7 Day 1 — No Circulating Free Deoxyribonucleic Acid (cfDNA) Detected5235
Cycle 7 Day 1 — Other (Sample failed analysis, uninformative, or not analyzed.)32
SecondaryNumber of Participant With ALK Fusion Variant in Plasma Circulating Nucleic Acid (CNA) Analysis at Screening, Cycle 2 Day 1 and Cycle 7 Day 1

The analysis of ALK fusion variant in plasma CNA was performed by NGS and the number of participants with fusion variants at Screening, Cycle 2 Day 1 and Cycle 7 Day 1 is presented here. In the table below, EML4-ALK is the abbreviation of echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase.

Time frame:
at Screening, Cycle 2 Day 1 and Cycle 7 Day 1
Reported as:
Count of participants · Participants
Number of Participant With ALK Fusion Variant in Plasma Circulating Nucleic Acid (CNA) Analysis at Screening, Cycle 2 Day 1 and Cycle 7 Day 1
ParticipantsLorlatinibCrizotinib
at Screening — EML4-ALK Variant 11925
at Screening — EML4-ALK Variant 272
at Screening — EML4-ALK Variant 31821
at Screening — EML4-ALK Other159
at Screening — ALK Rearrangement Other24
at Screening — ALK Rearrangement Not Detected3236
at Screening — No cfDNA Detected3225
at Screening — Other (Sample failed analysis, uninformative, or not analyzed.)53
Cycle 2 Day 1 — EML4-ALK Variant 117
Cycle 2 Day 1 — EML4-ALK Variant 220
Cycle 2 Day 1 — EML4-ALK Variant 322
Cycle 2 Day 1 — EML4-ALK Other21
Cycle 2 Day 1 — ALK Rearrangement Other00
Cycle 2 Day 1 — ALK Rearrangement Not Detected6148
Cycle 2 Day 1 — No cfDNA Detected5358
Cycle 2 Day 1 — Other (Sample failed analysis, uninformative, or not analyzed.)42
Cycle 7 Day 1 — EML4-ALK Variant 105
Cycle 7 Day 1 — EML4-ALK Variant 201
Cycle 7 Day 1 — EML4-ALK Variant 304
Cycle 7 Day 1 — EML4-ALK Other01
Cycle 7 Day 1 — ALK Rearrangement Other02
Cycle 7 Day 1 — ALK Rearrangement Not Detected4834
Cycle 7 Day 1 — No cfDNA Detected5235
Cycle 7 Day 1 — Other (Sample failed analysis, uninformative, or not analyzed.)32

Adverse events

Collected over From the first dose of study treatment through end of study follow-up (infinite lag) or start of new anti-cancer therapy, whichever occurred first (assessed up to 33 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lorlatinib23/149 (15.4%)51/149 (34.2%)148/149 (99.3%)
Crizotinib28/142 (19.7%)39/142 (27.5%)140/142 (98.6%)
Most frequent serious events
Showing 10 of 91
Most frequent serious events
EventLorlatinibCrizotinib
PneumoniaInfections and infestations7/1495/142
DyspnoeaRespiratory, thoracic and mediastinal disorders4/1490/142
Respiratory failureRespiratory, thoracic and mediastinal disorders4/1490/142
PyrexiaGeneral disorders3/1493/142
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1492/142
Pleural effusionRespiratory, thoracic and mediastinal disorders2/1492/142
PneumonitisRespiratory, thoracic and mediastinal disorders2/1492/142
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/1492/142
Cardiac failureCardiac disorders2/1491/142
Pericardial effusionCardiac disorders2/1491/142
Most frequent other events
Showing 10 of 77
Most frequent other events
EventLorlatinibCrizotinib
HypertriglyceridaemiaMetabolism and nutrition disorders78/1496/142
DiarrhoeaGastrointestinal disorders32/14974/142
NauseaGastrointestinal disorders22/14974/142
Oedema peripheralGeneral disorders65/14944/142
Blood cholesterol increasedInvestigations59/1494/142
VomitingGastrointestinal disorders19/14955/142
Weight increasedInvestigations57/14918/142
HypercholesterolaemiaMetabolism and nutrition disorders53/1491/142
Alanine aminotransferase increasedInvestigations26/14948/142
ConstipationGastrointestinal disorders26/14941/142

Baseline characteristics

Age, Continuous
Age, Continuous(Years)LorlatinibCrizotinibTotal
Mean59.1 ± 13.1255.6 ± 13.5257.4 ± 13.41
Sex: Female, Male
Sex: Female, Male(Participants)LorlatinibCrizotinibTotal
Female8491175
Male6556121
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LorlatinibCrizotinibTotal
Race — White7272144
Race — Black or African American011
Race — Asian6565130
Race — Missing12921
08

Study locations

166 sites

Showing the first 100 of 166 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Liu G, Solomon BJ, Mazieres J, Kim DW, Cortinovis D, Inoue T, Sharma R, Thurm H, Polli A, Bauer TM. Kinetics and management of adverse events associated with lorlatinib after 5 years of follow-up in the CROWN study. Oncologist. 2025 Oct 1;30(10):oyaf287. doi: 10.1093/oncolo/oyaf287. PubMed 41124598 ↗
  • Wu YL, Kim HR, Soo RA, Zhou Q, Akamatsu H, Chang GC, Chiu CH, Hayashi H, Kim SW, Goto Y, Kato T, Zhou J, Lee VH, Nishio M, Han B, Kim DW, Lu S, Polli A, Martini JF, Toffalorio F, Wong CH, Mok T. First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study. J Thorac Oncol. 2025 Jul;20(7):955-968. doi: 10.1016/j.jtho.2025.02.021. Epub 2025 Feb 28. PubMed 40024442 ↗
  • Solomon BJ, Liu G, Felip E, K Mok TS, Soo RA, Mazieres J, Shaw AT, Marinis F, Goto Y, Wu YL, Kim DW, Martini JF, Messina R, Paolini J, Polli A, Thomaidou D, Toffalorio F, Bauer TM. Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer. Future Oncol. 2024 Dec;20(40):3377-3387. doi: 10.1080/14796694.2024.2406117. Epub 2024 Oct 3. PubMed 39360949 ↗
  • Solomon BJ, Liu G, Felip E, Mok TSK, Soo RA, Mazieres J, Shaw AT, de Marinis F, Goto Y, Wu YL, Kim DW, Martini JF, Messina R, Paolini J, Polli A, Thomaidou D, Toffalorio F, Bauer TM. Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. J Clin Oncol. 2024 Oct 10;42(29):3400-3409. doi: 10.1200/JCO.24.00581. Epub 2024 May 31. PubMed 38819031 ↗
  • Soo RA, Martini JF, van der Wekken AJ, Teraoka S, Ferrara R, Shaw AT, Shepard D, Calella AM, Polli A, Toffalorio F, Tomasini P, Chiu CH, Kowalski DM, Kim HR, Solomon BJ. Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC. J Thorac Oncol. 2023 Nov;18(11):1568-1580. doi: 10.1016/j.jtho.2023.05.021. Epub 2023 Jun 7. PubMed 37295609 ↗
  • Solomon BJ, Bauer TM, Mok TSK, Liu G, Mazieres J, de Marinis F, Goto Y, Kim DW, Wu YL, Jassem J, Lopez FL, Soo RA, Shaw AT, Polli A, Messina R, Iadeluca L, Toffalorio F, Felip E. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med. 2023 Apr;11(4):354-366. doi: 10.1016/S2213-2600(22)00437-4. Epub 2022 Dec 16. PubMed 36535300 ↗
  • Solomon BJ, Bauer TM, Ignatius Ou SH, Liu G, Hayashi H, Bearz A, Penkov K, Wu YL, Arrieta O, Jassem J, Calella AM, Peltz G, Polli A, Thurm H, Mok T. Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study. J Clin Oncol. 2022 Nov 1;40(31):3593-3602. doi: 10.1200/JCO.21.02278. Epub 2022 May 23. PubMed 35605188 ↗
  • Solomon BJ, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Shaw AT. Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer. Future Oncol. 2021 Dec 1;17(34):4649-4656. doi: 10.2217/fon-2021-0904. Epub 2021 Sep 29. PubMed 34585621 ↗
  • Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ; CROWN Trial Investigators. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. N Engl J Med. 2020 Nov 19;383(21):2018-2029. doi: 10.1056/NEJMoa2027187. PubMed 33207094 ↗
  • Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, Gainor JF, Johnson M, Dietrich J, James LP, Clancy JS, Chen J, Martini JF, Abbattista A, Solomon BJ. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017 Dec;18(12):1590-1599. doi: 10.1016/S1470-2045(17)30680-0. Epub 2017 Oct 23. PubMed 29074098 ↗
  • Gainor JF, Shaw AT. J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer. Lancet. 2017 Jul 1;390(10089):3-4. doi: 10.1016/S0140-6736(17)31074-7. Epub 2017 May 10. No abstract available. PubMed 28501139 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Mar 2020, 34 months.

Results were first posted in Apr 2021, 1 year after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 34 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2017
First posted
Feb 14, 2017
StartActual
Apr 27, 2017
Primary completionActual
Mar 20, 2020
CompletionEst.
Dec 31, 2028
Results first posted
Apr 1, 2021
Last update
Nov 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03052608
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 14, 2017
Start date
Apr 27, 2017
Primary completion
Mar 20, 2020
Completion
Dec 31, 2028 (estimated)
Results posted
Apr 1, 2021
Last update
Nov 25, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lorlatinib

Start the discussion